Peter MD review
One account across six verticals — TRT, ED, weight loss, GLP-1, men's hair loss and NAD+ — from a physician-prescribed telehealth brand running since 2021, at a renewal price ($249/mo tirzepatide) well above its own $149 first-month headline.
- Semaglutide
- $149/mo first-time (Level 1), $139/mo returning (Level 2)
- Tirzepatide
- $149 first month, then $249/mo billed quarterly
- Coverage
- Varies by treatment — excluded in several states (marketing pages list AL/ID; the affiliate program's own disclosure is wider)
- Brand-name
- Compounded only
Semaglutide · modeled / year
$1,788
Tirzepatide · modeled / year
$2,988
Pricing verified August 2026
The Index scorecard
Peter MD scored on our six Cost-Efficiency Index factors. See the methodology.
Where the value is
- Broadest cross-category catalog in this ranking under one account: TRT, ED, non-GLP-1 weight loss, GLP-1 (semaglutide/tirzepatide), men's hair loss and NAD+, plus sermorelin
- Physician-prescribed, nationwide telehealth brand operating since 2021 (Miami, FL HQ)
- Sermorelin ($585 for a 12-week supply, ~$195/mo) and NAD+ ($369 for an 8-10 week supply, ~$147-184/mo) sit in the same catalog as the GLP-1 line for anyone consolidating multiple scripts
- TRT (testosterone cypionate) starts at $79/mo on a 12-month plan for readers whose real interest is hormone therapy alongside weight loss
The tradeoffs
- Tirzepatide's $149 first-month rate steps up to $249/mo billed quarterly — the number that matters for budgeting is the renewal price, not the headline
- Semaglutide pricing depends on tier: $149/mo first-time (Level 1) vs $139/mo returning (Level 2), with different total costs ($447 vs $834) over different supply windows, so the all-in cost is not a single number
- State restrictions vary by treatment and are wider than what the customer-facing marketing pages disclose — the affiliate program's own list excludes several additional states (AR, CA, IA, KY, LA, MA, MI, NC, SC) beyond the AL/ID the marketing pages show
- Customer reviews are mixed
- No FDA-approved brand-name route disclosed — GLP1 + B12 is compounded, not branded Wegovy/Ozempic/Mounjaro/Zepbound
The bottom line
Best for: Someone who wants a single telehealth account to also cover TRT, hair loss, ED or NAD+ alongside a GLP-1 script, and who will read past the first-month price before budgeting the ongoing cost. One account across six verticals — TRT, ED, weight loss, GLP-1, men's hair loss and NAD+ — from a physician-prescribed telehealth brand running since 2021, at a renewal price ($249/mo tirzepatide) well above its own $149 first-month headline.
Ranked #54 of 539 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.
Compare with other providers
All 538 other providers we've modeled, in Cost-Efficiency Index order. See the ranked alternatives to Peter MD.
- #60Nalena— Nalena is a women-focused, GLP-1-only telehealth platform offering compounded semaglutide and tirzepatide with medication included — no separate membership or visit fees.74/100
- #61NextMeds— NextMeds is a compounded-GLP-1 telehealth platform naming a real clinical group (Lion MD, led by two NPI-verifiable physicians) and six named compounding pharmacies — unusually transparent on that front.74/100
- #62Science & Co— Declares in its own footer that it is not a compounding facility, and explains its own asterisk in its own FAQ — two disclosures most of this market never makes.74/100
- #63Gala Health— Every dose at one published price, with the whole price list visible before you hand over an email — but the only terms it sells on are a yearly subscription at $179 or a three-month plan at $199, so there is no monthly number here to compare with anyone else's.71/100
- #64Direct Meds— The widest set of routes in this ranking — sublingual and injection on both semaglutide and tirzepatide, every SKU priced in the open — sold well above the median, on a plan that only ever bills against a 90-day supply.71/100
- #65He & She MD— He & She MD is a nationwide telehealth weight-loss clinic offering compounded semaglutide and tirzepatide (injectable, oral, or microdose) plus brand-name access.71/100
The 18 programs nearest this one
Pricing, states and verification reflect Peter MD's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on Peter MD's site. Not medical advice; see our disclosure.